{"id":"NCT01911221","sponsor":"Novartis Vaccines","briefTitle":"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","officialTitle":"A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-08","primaryCompletion":"2014-04","completion":"2014-04","firstPosted":"2013-07-30","resultsPosted":"2014-10-31","lastUpdate":"2017-06-08"},"enrollment":13,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Prevention of the Meningococcal Disease"],"interventions":[{"type":"BIOLOGICAL","name":"rMenB+OMV NZ","otherNames":[]}],"arms":[{"label":"rMenB+OMV NZ","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the immunogenicity and safety of the rMenB+OMV NZ in an adult population potentially at risk for meningococcal disease (e.g. lab workers).","primaryOutcome":{"measure":"Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule","timeFrame":"Day1 and Day 91","effectByArm":[{"arm":"rMenB+OMV NZ","deltaMin":1.18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":13},"commonTop":["INJECTION SITE PAIN","INJECTION SITE ERYTHEMA","HEADACHE","FATIGUE","INJECTION SITE INDURATION"]}}